Mineralys Therapeutics, Inc. (MLYS)

Market Cap	476.43M
Revenue (ttm)	n/a
Net Income (ttm)	-177.81M
Shares Out	49.84M
EPS (ttm)	-3.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	333,943
Open	9.69
Previous Close	9.53
Day's Range	9.37 - 9.85
52-Week Range	8.58 - 16.91
Beta	1.45
Analysts	Strong Buy
Price Target	27.00 (+182.43%)
Earnings Date	Feb 12, 2025

About MLYS

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company’s clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients w...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 10, 2023
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: MLYS
• Website: https://mineralystx.com

Analyst Forecast

According to 2 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price forecast is $27.0, which is an increase of 182.43% from the latest price.

Price Target

$27.0

(182.43% upside)

Analyst Consensus: Strong Buy